Unicycive

• locale

  United States

• market

  STOCKS

• industry

  Biotechnology

• website

  unicycive.com/

• ipo date

  Jul 12, 2021

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.